OOIR: Observatory of International Research

Papers

(The H4-Index of Open Forum Infectious Diseases is 47. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019	263
Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options	201
Lessons Learned From the First 10 Consecutive Cases of Intravenous Bacteriophage Therapy to Treat Multidrug-Resistant Bacterial Infections at a Single Center in the United States	179
C-Reactive Protein Level May Predict the Risk of COVID-19 Aggravation	171
Monkeypox: A Contemporary Review for Healthcare Professionals	146
Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)	136
Long COVID and Post-infective Fatigue Syndrome: A Review	125
Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19	119
Postacute COVID-19: An Overview and Approach to Classification	118
An “Infodemic”: Leveraging High-Volume Twitter Data to Understand Early Public Sentiment for the Coronavirus Disease 2019 Outbreak	112
Serum Iron Level as a Potential Predictor of Coronavirus Disease 2019 Severity and Mortality: A Retrospective Study	100
Prolonged and Late-Onset Symptoms of Coronavirus Disease 2019	95
Characterization of Bacterial and Fungal Infections in Hospitalized Patients With Coronavirus Disease 2019 and Factors Associated With Health Care-Associated Infections	85
Prevalence of Co-infection at the Time of Hospital Admission in COVID-19 Patients, A Multicenter Study	82
Infectious Complications Following CD19 Chimeric Antigen Receptor T-cell Therapy for Children, Adolescents, and Young Adults	82
Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19	81
Prolonged Low-Dose Methylprednisolone in Patients With Severe COVID-19 Pneumonia	80
Olfactory Dysfunction in Coronavirus Disease 2019 Patients: Observational Cohort Study and Systematic Review	78
Persistent Symptoms and Association With Inflammatory Cytokine Signatures in Recovered Coronavirus Disease 2019 Patients	72
Coronavirus Disease 2019–Associated Invasive Fungal Infection	71
Changing the Use of HIV Pre-exposure Prophylaxis Among Men Who Have Sex With Men During the COVID-19 Pandemic in Melbourne, Australia	69
Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018	67
Sources of Vaccine Hesitancy: Pregnancy, Infertility, Minority Concerns, and General Skepticism	65
Tecovirimat for the Treatment of Human Monkeypox: An Initial Series From Massachusetts, United States	64
Transmission of SARS-CoV-2 in Public Transportation Vehicles: A Case Study in Hunan Province, China	64

SARS-CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response	61
CD8+ T-Cell Responses in COVID-19 Convalescent Individuals Target Conserved Epitopes From Multiple Prominent SARS-CoV-2 Circulating Variants	60
Identification of Distinct Long COVID Clinical Phenotypes Through Cluster Analysis of Self-Reported Symptoms	60
Secondary Bacterial Infections in Critical Ill Patients With Coronavirus Disease 2019	59
Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era	59
Fever and Fever of Unknown Origin: Review, Recent Advances, and Lingering Dogma	56
Risk of Clinical Severity by Age and Race/Ethnicity Among Adults Hospitalized for COVID-19—United States, March–September 2020	56
Persistence, Magnitude, and Patterns of Postacute Symptoms and Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for Measurement	55
Invasive Aspergillosis as an Under-recognized Superinfection in COVID-19	54
Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection	54
The Longest Persistence of Viable SARS-CoV-2 With Recurrence of Viremia and Relapsing Symptomatic COVID-19 in an Immunocompromised Patient—A Case Study	54
Risk of Long COVID in People Infected With Severe Acute Respiratory Syndrome Coronavirus 2 After 2 Doses of a Coronavirus Disease 2019 Vaccine: Community-Based, Matched Cohort Study	54
A Distinct Phylogenetic Cluster of Indian Severe Acute Respiratory Syndrome Coronavirus 2 Isolates	53
SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar	52
Sexually Transmitted Infection Diagnoses and Access to a Sexual Health Service Before and After the National Lockdown for COVID-19 in Melbourne, Australia	52
Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients	52
SARS-CoV-2 Seroconversion and Viral Clearance in Patients Hospitalized With COVID-19: Viral Load Predicts Antibody Response	50
A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease	48
Staphylococcus aureus Bacteremia in Patients Infected With COVID-19: A Case Series	48
The Clinical Course of COVID-19 in the Outpatient Setting: A Prospective Cohort Study	47
Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients	47
In-Hospital Illicit Drug Use and Patient-Directed Discharge: Barriers to Care for Patients With Injection-Related Infections	47